Viewing Study NCT00035035


Ignite Creation Date: 2025-12-24 @ 10:31 PM
Ignite Modification Date: 2026-01-01 @ 12:44 PM
Study NCT ID: NCT00035035
Status: COMPLETED
Last Update Posted: 2006-07-19
First Post: 2002-05-02
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.
Sponsor: Eli Lilly and Company
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Eligibility Module Contacts Locations Module